Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Eden vs Primary Clinic (Direct GLP)

Two GLP-1 desks, one scoreboard. We put Eden and Primary Clinic (Direct GLP) head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 3 · Grade A−

Eden

Visit Eden Full brief →
vs
No. 186 · Grade C

Primary Clinic (Direct GLP)

Visit Primary Clinic (Direct GLP) Full brief →

The verdict

Eden takes this head-to-head.

Eden scores 91 to 67 on our six-factor Brief Score — A polished, high-disclosure program with strong nationwide coverage — you pay more, but you know exactly what you're paying for.

That doesn't make Primary Clinic (Direct GLP) a bad call — it's best for readers who want glp-1 at wholesale cost inside a direct primary care membership. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
89
48
Supply Reliability
92
69
Transparency
93
88
Access Breadth
90
64
Clinical Oversight
92
77
Track Record
89
57
EdenBrief Score 91 · 67Primary Clinic (Direct GLP)

Price, coverage & the tracker

EdenPrimary Clinic (Direct GLP)
Brief Score91/100 (A−)67/100 (C)
Semaglutide$239/moFrom $65/mo (0.25 mg dose, compounded)
Tirzepatide$349/moFrom $110/mo (2.5 mg dose, compounded)
CoverageAll 50 states10 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Eden: Premium line steady; high supply-chain disclosure keeps our confidence high.

Primary Clinic (Direct GLP): New to the tracker on 1 August 2026. The published line reads From $65/mo (0.25 mg dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.